%0 Journal Article
%T Years of sorafenib investigation in advanced non-small cell lung cancer: is there a ‘NExUS’ linking an unsuccessful treatment and a potentially active one?
%A Metro, Giulio
%A Minotti, Vincenzo
%A Crinò, Lucio
%J Journal of Thoracic Disease
%D 2012
%B 2012
%9 
%! Years of sorafenib investigation in advanced non-small cell lung cancer: is there a ‘NExUS’ linking an unsuccessful treatment and a potentially active one?
%K 
%X Sorafenib, a multi-targeted receptor tyrosine-kinase inhibitor (TKI) with a supposedly predominant anti-angiogenic activity (inhibition of vascular endothelial growth factor receptor-2, -3 and platelet-derived growth factor ß), has been the subject of extensive clinical research in advanced non-small cell lung cancer (NSCLC).
%U https://jtd.amegroups.org/article/view/625
%V 4
%N 6
%P 635-638
%@ 2077-6624